Terms: = Leukemia AND KEAP1, INrf2, ENSG00000079999, 9817, Q14145, MGC9454, MGC4407, MGC20887, MGC1114, MGC10630, KLHL19, KIAA0132 AND Treatment
13 results:
1. Ovatodiolide induces autophagy-mediated cell death through the p62-keap1-Nrf2 signaling pathway in chronic myeloid leukemia cells.
Xia Q; Xie J; Zhang J; Zhang L; Zhou Y; Zhu B; Wu Y; Yang Z; Li J
Chem Biol Interact; 2024 Jan; 387():110819. PubMed ID: 38000454
[TBL] [Abstract] [Full Text] [Related]
2. Omics-based identification of an NRF2-related auranofin resistance signature in cancer: Insights into drug repurposing.
Falchetti M; Delgobo M; Zancanaro H; Almeida K; das Neves RN; Dos Santos B; Stefanes NM; Bishop A; Santos-Silva MC; Zanotto-Filho A
Comput Biol Med; 2023 Jan; 152():106347. PubMed ID: 36493734
[TBL] [Abstract] [Full Text] [Related]
3. Anti-Leukemic Activity of Brassica-Derived Bioactive Compounds in HL-60 Myeloid leukemia Cells.
Núñez-Sánchez MÁ; Martínez-Sánchez MA; Verdejo-Sánchez M; García-Ibáñez P; Oliva Bolarín A; Ramos-Molina B; Moreno DA; Ruiz-Alcaraz AJ
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362202
[TBL] [Abstract] [Full Text] [Related]
4. Identification of novel Nrf2/keap1 pathway mutations in pediatric acute lymphoblastic leukemia.
Akın-Balı DF; Aktas SH; Unal MA; Kankılıc T
Pediatr Hematol Oncol; 2020 Feb; 37(1):58-75. PubMed ID: 31661353
[TBL] [Abstract] [Full Text] [Related]
5. The Antioxidant from Ethanolic Extract of
Wang KC; Liu YC; El-Shazly M; Shih SP; Du YC; Hsu YM; Lin HY; Chen YC; Wu YC; Yang SC; Lu MC
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31010164
[No Abstract] [Full Text] [Related]
6. Functional Profiling Identifies Determinants of Arsenic Trioxide Cellular Toxicity.
Sobh A; Loguinov A; Yazici GN; Zeidan RS; Tagmount A; Hejazi NS; Hubbard AE; Zhang L; Vulpe CD
Toxicol Sci; 2019 May; 169(1):108-121. PubMed ID: 30815697
[TBL] [Abstract] [Full Text] [Related]
7. Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity.
Amodio N; Stamato MA; Juli G; Morelli E; Fulciniti M; Manzoni M; Taiana E; Agnelli L; Cantafio MEG; Romeo E; Raimondi L; Caracciolo D; Zuccalà V; Rossi M; Neri A; Munshi NC; Tagliaferri P; Tassone P
Leukemia; 2018 Sep; 32(9):1948-1957. PubMed ID: 29487387
[TBL] [Abstract] [Full Text] [Related]
8. Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties.
Wang YY; Yang YX; Zhe H; He ZX; Zhou SF
Drug Des Devel Ther; 2014; 8():2075-88. PubMed ID: 25364233
[TBL] [Abstract] [Full Text] [Related]
9. The NRF2-keap1 pathway is an early responsive gene network in arsenic exposed lymphoblastoid cells.
Córdova EJ; Martínez-Hernández A; Uribe-Figueroa L; Centeno F; Morales-Marín M; Koneru H; Coleman MA; Orozco L
PLoS One; 2014; 9(2):e88069. PubMed ID: 24516582
[TBL] [Abstract] [Full Text] [Related]
10. Identification of driver genes in hepatocellular carcinoma by exome sequencing.
Cleary SP; Jeck WR; Zhao X; Chen K; Selitsky SR; Savich GL; Tan TX; Wu MC; Getz G; Lawrence MS; Parker JS; Li J; Powers S; Kim H; Fischer S; Guindi M; Ghanekar A; Chiang DY
Hepatology; 2013 Nov; 58(5):1693-702. PubMed ID: 23728943
[TBL] [Abstract] [Full Text] [Related]
11. Identification of aldo-keto reductases as NRF2-target marker genes in human cells.
Jung KA; Choi BH; Nam CW; Song M; Kim ST; Lee JY; Kwak MK
Toxicol Lett; 2013 Mar; 218(1):39-49. PubMed ID: 23305850
[TBL] [Abstract] [Full Text] [Related]
12. Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis.
Morales AA; Gutman D; Cejas PJ; Lee KP; Boise LH
J Biol Chem; 2009 May; 284(19):12886-95. PubMed ID: 19279006
[TBL] [Abstract] [Full Text] [Related]
13. Control of cellular redox status and upregulation of quinone reductase NQO1 via Nrf2 activation by alpha-lipoic acid in human leukemia HL-60 cells.
Elangovan S; Hsieh TC
Int J Oncol; 2008 Oct; 33(4):833-8. PubMed ID: 18813798
[TBL] [Abstract] [Full Text] [Related]
